Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01055106 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis
A Phase 2 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT01055106 is a Phase 2 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 255 participants.
The verdict
NCT01055106, a Phase 2 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy and safety of GW05 administered in 3 regimens versus metronidazole 0.75% for the treatment of bacterial vaginosis.
Interventions
- DRUG Metronidazole
- DRUG GW05
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01055106
The ClinicalTrials.gov registry entry for NCT01055106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Metronidazole is the first listed.
NCT01055106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01055106 about?
NCT01055106 is a clinical study titled "Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis". The objective of this study is to evaluate the efficacy and safety of GW05 administered in 3 regimens versus metronidazole 0.75% for the treatment of bacterial vaginosis.
What is the current status of trial NCT01055106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2010-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01055106?
The interventions under investigation include: Metronidazole (DRUG), GW05 (DRUG).
Who is sponsoring clinical trial NCT01055106?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.